PTEN and ovarian cancer: In another study, patients with advanced ascitic ovarian cancer have been explored, providing further evidence in favor of very frequent abnormalities of the PI3K signaling pathway: PI3KCA mutations were present in 5% of samples; amplification of PI3KCA and AKT2 and deletion of PTEN were seen in 12%, 10% and 27% of samples, respectively [7].